Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript
CLOV - Clover Health Investments, Corp.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$3.33
DETAILS
HIGH:
$6.00
LOW:
$1.80
MEDIAN:
$2.75
CONSENSUS:
$3.33
DOWNSIDE:
6.20%
Stock News
Clover Health Q1 Earnings Meet Estimates, Sales Beat, Membership Rises
CLOV posts 62% revenue growth in Q1 as Medicare Advantage membership surges and AI-driven care initiatives boost profitability.
Clover Health Investments, Corp. (CLOV) Meets Q1 Earnings Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.
Clover Health Reports First Quarter 2026 Results
Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross Profit Market-leading Medicare Advantage membership growth with underlying trends tracking in line with expectations Expect to meet or exceed full year 2026 outlook across all metrics, including achieving first full year GAAP Net Income profitability Financial Results: First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-year First quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-year First quarter 2026 Consolidated Gross Profit of $160 million, up 47% year-over-year, and Adjusted EBITDA of $40 million, up 56% year-over-year Full Year 2026 Guidance: Average Medicare Advantage membership of 154,000 - 158,000, representing 46% growth year-over-year at the midpoint Total revenues between $2.81 billion and $2.92 billion, representing 49% growth year-over-year at the midpoint Consolidated Gross Profit between $470 million and $510 million, representing 38% growth year-over-year at the midpoint Adjusted EBITDA profitability between $50 million and $70 million GAAP Net Income between $0 million and $20 million WILMINGTON, Del., May 06, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the first quarter 2026.
Butterfly Network, Inc. (BFLY) Reports Q1 Loss, Beats Revenue Estimates
Butterfly Network, Inc. (BFLY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.06 per share a year ago.
Here's Why You Should Retain Clover Stock in Your Portfolio for Now
CLOV rides strong membership growth and an AI-driven care model, but rising costs and policy risks cloud the near-term outlook.
Clover Health to Report First Quarter 2026 Financial Results on May 6, 2026
WILMINGTON, Del., April 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, May 6, 2026.
Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership
WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, in partnership with HealthEx , today announced a new collaboration that enables Clover Medicare Advantage (MA) members to securely access and share clinical records and claims data, further advancing patients rights to access and share their own health data, which is central to federal interoperability efforts.
Clover Health Investments Target of Unusually Large Options Trading (NASDAQ:CLOV)
Clover Health Investments, Corp. (NASDAQ: CLOV - Get Free Report) saw unusually large options trading activity on Monday. Traders acquired 37,742 call options on the stock. This represents an increase of 42% compared to the average volume of 26,552 call options. Insider Buying and Selling at Clover Health Investments In related news, CEO Brady Patrick Priest
Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026
WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that Peter Kuipers is stepping down as the Chief Financial Officer of the Company, effective March 30, 2026. Mr. Kuipers will remain with the Company in an advisory capacity through April 24, 2026 to support a smooth transition and handoff. Mr. Kuipers and the Company noted that his departure does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Clover Health Investments, Corp. (NASDAQ:CLOV) Receives $2.90 Consensus PT from Analysts
Clover Health Investments, Corp. (NASDAQ: CLOV - Get Free Report) has received an average recommendation of "Hold" from the five ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the
Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients
SAN FRANCISCO, March 19, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), and a leading AI-powered physician-enablement platform today released a whitepaper titled “Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Flu Preventative Care.” The analysis examines the role of CA's real-time clinical insights on immunization rates and flu-related acute care utilization within Clover Health's Medicare Advantage (MA) population.
Clover Health: Strong Growth, Improving Margins, And A Mispriced Stock
Clover Health is positioned for a major turnaround, with operations and profitability metrics improving sharply despite market skepticism. CLOV projects 46% membership growth and 49% revenue growth for 2026, guiding toward its first full year of positive GAAP net income. Operating leverage is materializing as SG&A improves, member retention exceeds 95%, and mature cohorts deliver over $200 monthly profit per member.
UPDATED – Moving from Pledge to Production, Clover Health is Now Live on Kno2, Participating in Recently Announced Federal Interoperability Initiatives
NOTICE: This is an updated version of a press release originally issued March 4, 2026 by Clover Health Investments, Corp. (Nasdaq: CLOV). Language has been updated to further refine the description of Clover Health's participation in federal interoperability initiatives.
Clover Health Enters Collaboration to Be Part of CMS Aligned Network
CLOV jumped 8% after partnering with Kno2 to become the first payer live on a CMS Aligned Network, enabling real-time patient access to clinical and claims data.
Here's Why You Should Retain Clover Stock in Your Portfolio for Now
CLOV rides 38% Medicare Advantage growth and rising EBITDA, but higher medical costs and policy risks cloud its near-term margin outlook.
Clover Health Moves from Pledge to Production, Becomes The First Payer Live on a CMS Aligned Network
WILMINGTON, Del., March 04, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, and Kno2, healthcare's leading communication network, today announced a collaboration enabling Clover Health to be the first payer live on a CMS Aligned Network and TEFCA.
Critical Comparison: Clover Health Investments (NASDAQ:CLOV) and Strata Skin Sciences (NASDAQ:SSKN)
Strata Skin Sciences (NASDAQ: SSKN - Get Free Report) and Clover Health Investments (NASDAQ: CLOV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Institutional and Insider Ownership 32.4%
Clover Health Q4 Earnings Meet Estimates, Sales Beat, Membership Rises
CLOV Q4 loss matches estimates. Revenues jump 45%.
Clover Health Investments, Corp. (CLOV) Q4 2025 Earnings Call Transcript
Clover Health Investments, Corp. (CLOV) Q4 2025 Earnings Call Transcript
Price Targets
Clover Health (CLOV) PT Raised to $3 at Leerink Partners
$3.00
(was $2.92)
Whit Mayo
·
Leerink Partners
Clover Health initiated with a Buy at Craig-Hallum
$6.00
(was $3.16)
Matt Hewitt
·
Craig-Hallum
Clover Health (CLOV) PT Raised to $2.50 at Canaccord Genuity
$2.50
(was $1.86)
Richard Close
·
Canaccord Genuity
Citigroup Maintains Neutral on Clover Health Investments, Lowers Price Target to $1.8
$1.80
(was $1.44)
Citigroup